Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying users area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Moderna Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Accounts payable
Manufacturing
Clinical trials
Raw materials
Loss on future firm purchase commitments
Other external goods and services
Royalties
Compensation-related
Development operations
Other
Accrued liabilities
Deferred revenue
Income taxes payable
Financing lease liabilities, current
Operating lease liabilities, current
Other
Other current liabilities
Current liabilities
Deferred revenue, non-current
Operating lease liabilities, non-current
Financing lease liabilities, non-current
Deferred lease obligation, non-current
Lease financing obligation
Other non-current liabilities
Non-current liabilities
Total liabilities
Preferred stock, $0.0001; no shares issued or outstanding
Common stock, par value $0.0001
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings (accumulated deficit)
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Moderna Inc. current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Moderna Inc. non-current liabilities as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 and from 2021 to 2022.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Moderna Inc. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Moderna Inc. stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 and from 2021 to 2022.